ModifiedUnitedHealthcarePolicy CSNCT0521.03

Noncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds (for North Carolina Only)

State-specific UnitedHealthcare medical policy governing use and coverage of noncontact normothermic wound warming, low-frequency ultrasound therapies (including MIST/MIST Therapy) and noncontact real-time fluorescence wound imaging for bacterial presence in North Carolina members.

Policy Summary

PayerUnitedHealthcare

PolicyNoncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds (for North Carolina Only)

Policy CodePolicy CSNCT0521.03

Change TypeState-specific version createdevidence/references updated

Effective DateAug 1, 2025

Next Review Date

Key ActionWhen seeking coverage, providers should follow payer prior authorization processes and submit clinical justification and documentation as required by the member's benefit plan.

SourceLink

POLICY UPDATE CHANGES

Created state-specific policy version for the state of North Carolina (no change to coverage guidelines).

Updated Clinical Evidence and References sections to reflect the most current information.

NC-onlypolicy application

Insufficient evidencecoverage rationale for all three technologies

3interventions reviewed

0598T,0599T,97610

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

ECRI 2021/2024evidence assessment

Coverage Determinations and Evidence Summary

Not medically necessary / Unproven

Not medically necessary when used to treat wounds due to insufficient evidence.

Coverage Rationale: Warming therapy (noncontact normothermic wound therapy) and low-frequency ultrasound therapy are unproven and not medically necessary for treating wounds due to insufficient evidence of efficacy; noncontact real-time fluorescence wound imaging for bacterial presence is unproven and not medically necessary due to insufficient evidence of safety and/or efficacy.

Policy states these technologies are considered unproven and not medically necessary.

Ultrasound — evidence summary

Evidence summaries for modalities reviewed in this section.

Low/high-frequency ultrasound evidence summary: Randomized trials and systematic reviews report mixed results. Small RCTs (eg, Beheshti et al., n=90) administering ultrasound three times weekly found reductions in wound size, pain, and edema versus compression alone but had limitations including lack of masking and short follow-up. Larger multicenter RCT evidence (Watson et al., VenUS III, n=337) found no improvement in time to healing or quality of life with weekly low‑dose, high‑frequency ultrasound and reported more adverse events in the ultrasound arm. Systematic reviews and additional RCTs of noncontact low‑frequency airborne ultrasound show heterogeneous results and variable study quality.

See Beheshti 2014, Watson 2011, and referenced reviews/trials.

Fluorescence imaging — diagnostic accuracy and clinical utility

Handheld noncontact fluorescence imaging devices — diagnostic accuracy and clinical outcomes.

Diagnostic performance: Multiple observational and prospective studies report higher sensitivity and improved detection of moderate‑to‑heavy bacterial loads (commonly referenced at ≥10^4 CFU/g) with fluorescence imaging compared with clinical signs or routine swab culture. Reported diagnostic sensitivity ranges are high in several cohorts (eg, Mayer et al. sensitivity 84% vs CSB 44%), and studies report high proportions of positive culture among fluorescence‑indicated swabs (eg, Hurley et al. found 95.4% positive growth among fluorescence‑directed swabs).

Diagnostic accuracy vs gold‑standard and culture reported in Mayer 2024, Hurley 2019, Armstrong 2023, Le 2020.

Clinical utility and patient outcomes: Small randomized pilot trials and observational studies suggest that fluorescence‑guided interventions (for example, targeted debridement informed by MolecuLight imaging) may be associated with greater wound‑area reduction or higher proportions healed in pilot studies (eg, Rahma et al. pilot RCT showed 45% vs 22% healed at 12 weeks), but these studies are underpowered and limited. Larger, well‑powered RCTs demonstrating consistent improvement in patient‑centered outcomes are lacking; an evidence assessment by ECRI concluded evidence is inconclusive for improvement in patient outcomes.

See Rahma 2022 pilot RCT, Derwin 2023 observational WAR data, and ECRI assessment.

Fluorescence imaging (diagnostic utility vs outcomes)

Evidence summary and recommended use context.

Fluorescence imaging evidence: Evidence indicates devices such as the MolecuLight i:X detect moderate‑to‑heavy bacterial burden with greater sensitivity than clinical signs alone and can guide sampling and targeted debridement; however, randomized trials demonstrating improved patient‑centered outcomes or wound‑healing benefit are lacking, and systematic evidence assessments (ECRI 2021, updated 2024) judged the evidence inconclusive. Fluorescence imaging may be used adjunctively with clinical assessment but should not be considered established to improve healing outcomes until higher‑quality RCT data are available.

ECRI concluded evidence is inconclusive and additional RCTs are needed; small pilot RCTs and observational studies suggest possible benefit but are not definitive.

Noncontact ultrasound and MIST systems

Evidence summary and guideline recommendations.

Ultrasound adjunctive use: Guidelines and reviews indicate low‑frequency ultrasound (including MIST systems) may support healing, reduce pain, or aid debridement when used in combination with standard care (eg, compression, debridement, appropriate dressings) for non‑healing venous or mixed‑etiology ulcers, but the quantity and quality of evidence are limited. NICE stated MIST Therapy shows potential but evidence is insufficient to support routine adoption; AAWC notes limited evidence for enduring benefit and application parameters. Overall, evidence quality and inconsistent trial results preclude definitive recommendations for routine coverage.

See AAWC recommendations, NICE Medtech briefing and MIST guidance.

Warming therapy

Evidence summary.

Warming therapy: Noncontact warming therapy (local warming/NNWT) has insufficient evidence of healing efficacy to inform management decisions for venous ulcers or other chronic wounds. Recommendations note limited or pilot data only, and guidelines indicate evidence is inadequate to support adoption as a proven adjunct therapy.

AAWC and cited pilot studies report limited evidence; no high‑quality RCTs demonstrate durable healing benefit.

No specific clinical exclusions are listed in this policy excerpt beyond the overall determination that the reviewed technologies are unproven and not medically necessary. The policy applies its coverage stance (unproven / not medically necessary) to noncontact warming therapy (NNWT), low-frequency ultrasound therapies, and noncontact real-time fluorescence wound imaging based on insufficient evidence of efficacy and/or safety.

The document does not specify explicit patient- or wound-type exclusions for use of the devices. It does note limitations of fluorescence imaging devices, including limited detection depth (~1.5 mm) and inability to detect some bacteria (non‑porphyrin‑producing species), which may affect diagnostic performance and should be considered when interpreting device findings.

FDA clearance or 510(k) status is provided for informational purposes only. The policy explicitly states that FDA approval alone is not a basis for coverage and that regulatory clearance does not imply that a technology meets UnitedHealthcare coverage criteria.

Application of this policy must be performed in the context of the member's benefit plan. Federal, state, or contractually governed benefit plan requirements may differ from the policy and, in case of conflict, those requirements govern coverage decisions.

Recap of the coverage stance: Noncontact warming therapy (NNWT) and low-frequency ultrasound therapies are considered unproven and not medically necessary for treating wounds due to insufficient evidence. For fluorescence imaging, diagnostic studies show potential to detect bacterial burden, but the evidence is inconclusive for improving patient‑centered outcomes and therefore the technology is considered unproven for routine coverage.

Evidence from a large multicenter randomized controlled trial (Watson et al., n=337) found that weekly, low‑dose, high‑frequency ultrasound given up to 12 weeks in addition to standard care did not increase ulcer healing rates, change time to healing, or improve quality of life, and was associated with more adverse events. Thus, the evidence is insufficient to support weekly low‑dose, high‑frequency ultrasound for 12 weeks as an effective therapy to increase healing rates.

Although studies report that fluorescence imaging (e.g., MolecuLight i:X) can detect moderate‑to‑heavy bacterial loads with higher sensitivity than clinical signs alone, the clinical utility to improve patient‑centered outcomes or wound healing has not been established. A clinical evidence assessment (ECRI) concluded evidence is inconclusive and additional randomized trials are needed to demonstrate safety and efficacy for improving outcomes.

Applicable Procedure and Supply Codes (Reference Only)

Applicable procedure codes (listed for reference)CPT

0598T	Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; first anatomic site (e.g., lower extremity).
0599T	Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; each additional anatomic site (e.g., upper extremity) (List separately in addition to code for primary procedure).
97610	Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day

Durable medical equipment / supply codesHCPCS

A6000	Noncontact wound-warming wound cover for use with the noncontact wound-warming device and warming card.
E0231	Noncontact wound-warming device (temperature control unit, AC adapter and power cord) for use with warming card and wound cover.
E0232	Warming card for use with the noncontact wound-warming device and noncontact wound warming- wound cover

Bacterial load thresholds referenced in studies (device detection thresholds vs lab CFU/g thresholds)

Device detection threshold (fluorescence imaging)Many studies report device detection correlating with bacterial loads >= 10^4 CFU/g (eg, Le et al., Armstrong et al., ECRI evidence summaries).

Laboratory culture threshold (reference comparator)Standard quantitative tissue-culture thresholds commonly referenced at 10^5 CFU/g for clinically significant infection in some analyses.

Study-reported bacterial-load rangeStudies evaluating fluorescence imaging compared detection across ranges from 10^4 to 10^9 CFU/g; in Armstrong et al. 93.9% of confirmed ulcers had >10^4 CFU/g.

Clinical implicationFluorescence-guided sampling and intervention target areas with >=10^4 CFU/g in many studies, though lab definitions and clinical significance vary between 10^4–10^5 CFU/g.

Billing, Authorization, and Documentation Considerations

Denial Risk

Denial Risk for Unproven Services

These technologies (noncontact normothermic wound therapy, low-frequency ultrasound therapy, and noncontact real-time fluorescence wound imaging) are considered experimental or unproven and may be denied as not medically necessary due to insufficient evidence of efficacy and/or safety. Providers should anticipate potential claim denials when submitting services related to these therapies unless coverage is specifically required by applicable federal, state, or contractual benefit plan language.

Affected services: noncontact normothermic wound therapy (NNWT), low frequency/noncontact ultrasound (e.g., MIST Therapy, UltraMIST), and noncontact real-time fluorescence wound imaging (e.g., MolecuLight i:X).
Anticipated action: prepare documentation to support medical necessity and check plan-specific coverage; expect denials where services are considered unproven.

Prior Authorization

Prior Authorization Not Specified in This Excerpt

Background and Rationale

Noncontact normothermic wound therapy (NNWT) applies radiant heat and a humid microenvironment to wounds with the intent of raising local temperature and increasing perfusion. The approach uses a noncontact wound cover and a warming unit to deliver heat to the wound surface as an adjunct to standard wound care.

Device and Therapy Definitions

Warming therapy definition (NNWT)

DefinitionNoncontact normothermic wound therapy (NNWT) applies radiant heat via a noncontact wound cover and a warming unit to maintain high humidity and raise wound temperature to increase blood flow and oxygen to the wound.

Delivery componentsTypical system includes a noncontact wound cover, warming unit (temperature control), and warming card or dressing to deliver heat and humidity.

Intended effectAims to increase perfusion and oxygenation at the wound bed to support healing; evidence for efficacy is limited.

Low-frequency ultrasound / MIST Therapy definition

DefinitionLow-frequency ultrasound / MIST Therapy uses an ultrasonic handset held ~1 cm from the wound with saline applied to generate a saline mist that carries low-level ultrasonic energy to the wound to cleanse and debride.

Document History and Updates

Policy Summary

PayerUnitedHealthcare

PolicyNoncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds (for North Carolina Only)

Policy CodePolicy CSNCT0521.03

Change TypeState-specific version createdevidence/references updated

Effective DateAug 1, 2025

Next Review Date

Key ActionWhen seeking coverage, providers should follow payer prior authorization processes and submit clinical justification and documentation as required by the member's benefit plan.

SourceLink

On This Page

Limitations across studies include small sample sizes, single‑center designs, limited clinician experience with devices, potential industry funding/conflicts of interest, device detection depth limitations (~1.5 mm), and inability to detect non‑porphyrin‑producing bacteria. These factors limit generalizability and the ability to conclude clinical‑outcome benefit.

See Mayer 2024, Armstrong 2023, Hurley 2019, ECRI 2021/2024.

This policy excerpt does not specify a uniform prior authorization requirement. Providers must follow the payer's standard prior authorization processes and verify whether prior authorization is required for the specific service under the member's benefit plan.

Check the member's benefit plan and payer portal for any service-specific prior authorization rules.
When required, submit appropriate clinical documentation per payer instructions.

Note

FDA Clearance/Approval Is Informational Only

FDA clearance or approval of a device is informational only and does not, by itself, establish that the related service is covered by UnitedHealthcare. Coverage decisions rely on the body of clinical evidence and applicable benefit plan requirements.

Examples: MolecuLight i:X 510(k) clearance; MIST Therapy system 510(k) — clearance does not imply coverage.
Providers should include clinical justification and outcome-focused evidence when seeking coverage.

Documentation Required

Evidence-Based Documentation Elements

When submitting requests for use of these technologies, include evidence-based documentation elements used in the clinical literature to support the clinical rationale and to enable medical review.

Baseline and follow-up wound measurements (digital and/or manual) and wound area reduction calculations.
Documented imaging outputs (e.g., fluorescence images) with interpretation linking findings to the proposed treatment plan.
Microbiology results or culture data when fluorescence suggests bacterial presence, and correlation between imaging findings and laboratory results.
Clinical course notes describing standard care measures provided (e.g., debridement, offloading, compression, dressings), response to prior therapies, and rationale for adjunctive use of the requested technology.
Duration, frequency, and parameters of the proposed therapy; prior conservative therapy attempts and outcomes.

Documentation Required

Documentation of Benefit Applicability

Coverage determinations must reference applicable federal, state, or contractual benefit plan requirements. Providers must verify benefit applicability before rendering or billing these services.

If plan language or applicable law mandates coverage for a specific service, follow those requirements even if the service is considered unproven in this policy.
When in doubt, obtain prior authorization and retain plan-specific correspondence in the medical record.

Note

Use With Standard Care

Clinical guidelines and the reviewed literature describe these technologies as adjuncts to, not replacements for, standard wound care. Use with standard care should be clearly documented.

Document that standard of care measures (e.g., debridement, compression, offloading, infection control, moisture-retentive dressings) have been implemented and optimized.
Clarify that the requested adjunctive therapy will be provided in addition to standard care, with specific clinical goals and measurable outcomes.

Billing Rule

Coding and Documentation Note

Providers should include the specific codes used for billing and ensure documentation supports the billed code(s). Listing of a code in this policy does not imply coverage.

Reference codes (not exhaustive): 0598T, 0599T (fluorescence imaging); 97610 (low frequency ultrasound); HCPCS A6000, E0231, E0232 (warming therapy components).
Ensure clinical records substantiate the medical necessity for the billed procedure code.

Transducer tip vibrates at ~40 kHz; mist transfers ultrasonic energy for wound cleansing, removal of slough, fibrin, exudate, and bacteria, and may stimulate cellular healing processes.

Regulatory/status noteNICE and professional guidance note MIST shows potential but published evidence is insufficient for routine adoption; FDA regulates MIST systems as Class II devices (see FDA references).

Noncontact real-time fluorescence wound imaging definition

DefinitionNoncontact real-time fluorescence wound imaging is a handheld, noncontact technique using violet light illumination to visualize bacterial autofluorescence in wounds in real time to localize bacterial presence and guide care.

Clinical useProvides images documenting fluorescent characteristics to assist sampling, targeted debridement, and treatment decisions; diagnostic accuracy versus standard methods has been reported in several studies.

LimitationsDetection depth is limited (~1.5 mm in some reports) and device does not detect non-porphyrin-producing bacteria; clinical outcome benefit remains unproven per evidence assessments.

Noncontact low frequency ultrasound (NCLF-US) definition

DefinitionNoncontact low frequency ultrasound (NCLF-US) is an airborne or noncontact ultrasound modality (often 20–40 kHz) applied without direct skin contact as an adjunct to standard wound care to reduce wound area and inflammation.

Application frequencySome small RCTs applied NCLF-US thrice weekly and reported greater wound-area reduction compared with less frequent or no treatment; evidence is mixed and requires larger trials.

Evidence contextSystematic reviews/meta-analyses and randomized trials (eg, Voigt et al., Watson et al., Rastogi et al.) have evaluated NCLF-US with heterogeneous results and variable quality.

Fluorescence wound imaging / MolecuLight i:X definition

DefinitionFluorescence wound imaging (e.g., MolecuLight i:X) is a handheld, noncontact device that captures violet-light-induced bacterial autofluorescence to identify areas of moderate-to-heavy bacterial burden in real time.

Diagnostic claimsStudies report higher sensitivity for detecting bacterial loads (often >=10^4 CFU/g) compared with clinical signs alone; evidence for improved patient outcomes is inconclusive.

Operational noteProduces images to guide sampling and targeted interventions; requires clinician training and does not replace microbiology testing when needed.

MolecuLight i:X — device-specific definition (FDA-cleared example)

Device-specific definitionMolecuLight i:X is a handheld, noncontact fluorescence imaging device cleared by the FDA (510(k)) to detect bacterial fluorescence in wounds and assist clinicians in identifying areas of moderate-to-heavy bacterial burden.

Intended useProvides real-time visualization of fluorescent bacteria to inform wound assessment, sampling location, and targeted debridement.

Evidence noteECRI assessment found diagnostic detection promising but concluded evidence is inconclusive for improving patient-centered outcomes; additional RCTs needed.

MIST Therapy System / UltraMIST definition (FDA regulated device)

DefinitionMIST Therapy System / UltraMIST is a noncontact, low-frequency ultrasound system that generates a saline mist carrying ultrasonic energy to cleanse and perform maintenance debridement of wounds.

Regulatory statusRegulated by the FDA as a Class II device; original MIST Therapy received 510(k) clearance in 2004 and UltraMIST received subsequent clearance (eg, K140782 for UltraMIST).

MechanismHandheld ultrasonic transducer vibrates at ~40 kHz; mist-borne ultrasonic energy removes slough, exudate, fibrin, and bacteria and may stimulate healing processes.

Noncontact low-frequency ultrasound general definition

General definitionNoncontact low-frequency ultrasound refers to ultrasound therapy delivered without direct contact (airborne or mist-mediated), typically in the 20–40 kHz range, used adjunctively for debridement and to potentially support healing of chronic wounds.

Clinical roleOften described as an adjunct to standard care (eg, compression, debridement, offloading) with possible benefits for pain reduction and wound healing in some studies.

Evidence limitationsSystematic reviews and guidance note limited quality and quantity of evidence, heterogeneous protocols, and uncertain long-term benefit and cost-effectiveness.

Noncontact low-frequency ultrasound (airborne ultrasound) — referenced randomized and controlled studies

Clinical trials referencedRandomized, double-blind, sham-controlled and other RCTs (eg, Rastogi et al. 2019; Watson et al. 2011; Yao et al. 2014) evaluated airborne/noncontact low-frequency ultrasound for diabetic foot ulcers and venous leg ulcers.

Study designsTrials include randomized double-blind sham-control designs and pilot randomized trials with varying application frequencies (eg thrice-weekly vs once-weekly vs sham).

Outcome findingsResults are mixed: some small trials reported improved wound-area reduction with frequent application, while larger multicenter RCTs found no healing-time benefit and variable adverse events; evidence quality is heterogeneous.

Fluorescence bacterial imaging definition — technique to identify moderate-to-heavy bacterial burden

TechniqueFluorescence bacterial imaging uses violet light excitation to elicit bacterial autofluorescence, producing real-time images that localize moderate-to-heavy bacterial burdens in wounds.

Diagnostic performanceStudies report higher sensitivity and accuracy for fluorescence imaging in detecting biofilm/bacterial loads (eg, Mayer et al. sensitivity 84% vs clinical signs 44%).

Clinical utility caveatAlthough diagnostic detection is promising, evidence for improved patient-centered outcomes (eg, wound healing) remains inconclusive and further RCTs are recommended.

Local warming therapy definition — therapeutic warming applied to chronic wounds

DefinitionLocal warming therapy refers to therapeutic application of heat (eg, radiant heat bandages or NNWT) to chronic wounds intended to raise wound temperature to improve perfusion.

Clinical evidenceOnly small pilot studies and limited systematic review data exist; NICE/AAWC summarize that warming therapy has insufficient evidence to inform routine use for chronic wounds.

Intended mechanismAims to increase blood flow and oxygen delivery to the wound bed via maintained warmth and humidity, but healing efficacy is not established.